Successful resolution of stromal keratitis and uveitis using canakinumab in a patient with chronic infantile neurologic, cutaneous, and articular syndrome: a case study

[1]  H. Takada,et al.  Safety and efficacy of canakinumab in Japanese patients with phenotypes of cryopyrin-associated periodic syndrome as established in the first open-label, phase-3 pivotal study (24-week results). , 2013, Clinical and experimental rheumatology.

[2]  P. Hawkins,et al.  Two-year results from an open-label, multicentre, phase III study evaluating the safety and efficacy of canakinumab in patients with cryopyrin-associated periodic syndrome across different severity phenotypes , 2011, Annals of the rheumatic diseases.

[3]  Helen J. Lachmann,et al.  In vivo regulation of interleukin 1β in patients with cryopyrin-associated periodic syndromes , 2009, The Journal of experimental medicine.

[4]  A. Prieur,et al.  Cryopyrinopathies: update on pathogenesis and treatment , 2008, Nature Clinical Practice Rheumatology.

[5]  C. Dinarello.  Mutations in cryopyrin: bypassing roadblocks in the caspase 1 inflammasome for interleukin-1beta secretion and disease activity. , 2007, Arthritis and rheumatism.

[6]  A. Martini,et al.  Pattern of interleukin-1beta secretion in response to lipopolysaccharide and ATP before and after interleukin-1 blockade in patients with CIAS1 mutations. , 2007, Arthritis and rheumatism.

[7]  K. Agematsu.  [Clinical observation of autoinflammatory diseases]. , 2007, Nihon Rinsho Men'eki Gakkai kaishi = Japanese journal of clinical immunology.

[8]  S. Holland,et al.  Neonatal-onset multisystem inflammatory disease responsive to interleukin-1beta inhibition. , 2006, The New England journal of medicine.

[9]  P. Hawkins,et al.  Spectrum of clinical features in Muckle-Wells syndrome and response to anakinra. , 2004, Arthritis and rheumatism.

[10]  D. Patel,et al.  Genomic-based therapy: targeting interleukin-1 for autoinflammatory diseases. , 2004, Arthritis and rheumatism.

[11]  E. Remmers,et al.  De novo CIAS1 mutations, cytokine activation, and evidence for genetic heterogeneity in patients with neonatal-onset multisystem inflammatory disease (NOMID): a new member of the expanding family of pyrin-associated autoinflammatory diseases. , 2002, Arthritis and rheumatism.

[12]  A. Fischer,et al.  Chronic infantile neurological cutaneous and articular syndrome is caused by mutations in CIAS1, a gene highly expressed in polymorphonuclear cells and chondrocytes. , 2002, American journal of human genetics.

[13]  A. Prieur,et al.  Chronic infantile neurological cutaneous and articular/neonatal onset multisystem inflammatory disease syndrome: ocular manifestations in a recently recognized chronic inflammatory disease of childhood. , 2000, Archives of ophthalmology.

[14]  A. Huttenlocher,et al.  Neonatal onset multisystem inflammatory disease. , 1995, The Journal of rheumatology.

[15]  Y. Fujita,et al.  Chronic, infantile, neurological, cutaneous and articular syndrome in Japan; two case reports. , 1994, Clinical and experimental rheumatology.

[16]  C. Griscelli,et al.  A chronic, infantile, neurological, cutaneous and articular (CINCA) syndrome. A specific entity analysed in 30 patients. , 1987, Scandinavian journal of rheumatology. Supplement.